Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
about
Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancerAdjuvant chemotherapy for resected early-stage non-small cell lung cancerExploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responsesRole of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new dataTargeting DNA Damage Response in the Radio(Chemo)therapy of Non-Small Cell Lung CancerSpotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so farAre three doses of stereotactic ablative radiotherapy (SABR) more effective than 30 doses of conventional radiotherapy?Post-operative radiation therapyRecent applications of chemosensitivity tests for colorectal cancer treatmentMediastinal lymph node dissection versus mediastinal lymph node sampling for early stage non-small cell lung cancer: a systematic review and meta-analysisSystemic and targeted therapies for early-stage lung cancerResearch Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer50 Years of progress in the systemic therapy of non-small cell lung cancerPooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.TCRP1 contributes to cisplatin resistance by preventing Pol β degradation in lung cancer cellsTrial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocolA new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinomaNon-small cell lung cancer: epidemiology, risk factors, treatment, and survivorshipThe Lake Wobegon effect: are all cancer patients above average?Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032Expression of CA125 and cisplatin susceptibility of pleural effusion-derived human lung cancer cells from a Thai patientPrognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancerA novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinomaDexamethasone reduces sensitivity to cisplatin by blunting p53-dependent cellular senescence in non-small cell lung cancerAssociations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancerHow individual participant data meta-analyses have influenced trial design, conduct, and analysisPredicting Prognosis of Early-Stage Non-Small Cell Lung Cancer Using the GeneFx® Lung SignaturePredictive and prognostic molecular markers for cancer medicineLung cancer in Brazil: epidemiology and treatment challenges.Timely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practice.Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer.Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer.Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancerERCC1 isoform expression and DNA repair in non-small-cell lung cancer.Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base.Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data.Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non-Small Cell Lung Cancer in the U.S. National Cancer Data Base.
P2860
Q21092374-C8E30C23-2B76-4AD7-AC65-5729FFFEF51EQ24187439-5109D5E8-3F1F-4123-97C3-300C55AE1852Q24604495-A47A0D72-2382-4018-9BBA-71CA5B9C8086Q24633254-6EE97F83-7C20-457B-9018-FFF8B94BF2D4Q26743378-5CA05664-E555-4F01-907B-A8485F6D2223Q26745776-B3A93DE5-B4D9-4B6F-8E61-811A5CABE696Q26823670-0FF374E8-C63C-4C94-A1CB-B8B37BE0F7B1Q26830376-69595190-D9C8-484A-9667-7F1A592EC9B9Q26851075-50A8D323-86A6-4332-A4CD-F00425C6E9B7Q26859343-CFC50FDB-626E-434A-8C48-138A625E4A9DQ26865490-B4A29BFC-525F-4E84-B78E-8A86FCF222D3Q27006349-ACA2EA6B-FFF6-424D-A24C-A6AC9A8478E3Q27014978-6741B97C-D29D-4A80-B733-E74DDF90118FQ27313799-93CFF0D3-E4DE-4FF0-8D49-2ADFBF4C8632Q28118898-94EF4181-C409-48AA-A9D1-BD5C462A7901Q28209997-4C1D31C0-8DD8-4F12-84DD-A1984E455656Q28247365-510DC470-3CFB-46EB-8F5E-98407B3293DBQ28278682-A717FFAB-1D38-4754-8900-21016223AE9CQ28303620-94D5FD41-9ED9-4A21-B2E3-D96DACB29B39Q28305717-EC658E4E-D9A9-4ED9-9A4B-41A82ECD220DQ28386717-9DB7C8BC-5E6C-4128-9F7C-A949CE5489C7Q28394974-2911F39C-7C1D-4AD2-AFCA-80C1F96E27C9Q28479007-CE268E60-2596-46AB-99B2-C3B3B4216FFEQ28484432-E8211B47-F064-457B-BC65-A92EC87BCB78Q28539722-0ECEF2E1-FC14-453B-A562-5F6191C89242Q28607751-6E33FFE7-FA57-4E00-834C-072E86A3F529Q28608174-BEA64AC1-7168-40F7-9475-C69FCA79223FQ28743108-FF878451-4A6E-44CF-9EE1-4535FD6D28D6Q30235908-2C7E52E1-F344-4089-845F-5B0B5D247128Q30249083-C483FDFA-11EF-4D97-A8F5-A476E9C0DF2AQ30358684-3982C807-3FBA-443E-8EF6-ED1885C7A08EQ30438068-74B5307B-AE31-4454-88A8-2B55276F9789Q30439235-826622AA-B716-4D0C-94BE-5ACB58F18BB2Q30487266-8138DC39-BB2A-4D9A-A64D-D646CE7B5568Q30498101-29365219-9E5E-4855-A605-225E8FC5FB29Q30539299-4E70914A-2DEC-4F93-B0E7-FA1FE31BE614Q30580553-490751DE-5211-411D-B322-699FDC11F4A2Q30868582-118ABD98-3705-4D00-B9B2-36446D9ABF11Q30976026-5FF08C48-EEC8-4080-8F3A-E8359A3D38A8Q31036733-6433F74F-89A1-4039-B565-39946F84B4A2
P2860
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Cisplatin-based adjuvant chemo ...... ed non-small-cell lung cancer.
@en
Cisplatin-based adjuvant chemo ...... ed non-small-cell lung cancer.
@nl
type
label
Cisplatin-based adjuvant chemo ...... ed non-small-cell lung cancer.
@en
Cisplatin-based adjuvant chemo ...... ed non-small-cell lung cancer.
@nl
prefLabel
Cisplatin-based adjuvant chemo ...... ed non-small-cell lung cancer.
@en
Cisplatin-based adjuvant chemo ...... ed non-small-cell lung cancer.
@nl
P2093
P50
P356
P1476
Cisplatin-based adjuvant chemo ...... ted non-small-cell lung cancer
@en
P2093
Ariane Dunant
Bengt Bergman
International Adjuvant Lung Cancer Trial Collaborative Group
Johan Vansteenkiste
P304
P356
10.1056/NEJMOA031644
P407
P577
2004-01-01T00:00:00Z